Patients with cholangiocarcinoma may derive benefit from treatment with TT-00420, which was recently given a fast track designation by the FDA.
The clinical-stage spectrum-selective kinase inhibitor TT-00420 was granted a fast track designation by the FDA for patients with cholangiocarcinoma who have no available standard treatment options, according to a press release from developer TransThera Sciences.1
The designation is based on results from a phase 1 study that assessed TT-00420 at several dose levels in patients with advanced or metastatic solid tumors, including triple-negative breast cancer and cholangiocarcinoma.2 Notably, at least 7 patients received 1 or more post-treatment efficacy assessments. Additionally, 2 patients with cholangiocarcinoma who received 8 mg and 10 mg of the agent, respectively, achieved a partial response (PR). Five other patients had stable disease.
Data from the study helped to support further exploration of TT-00420 in this patient population.
“Receiving fast track designation is an important milestone for the development of TT-00420,” Frank Wu, PhD, chief executive officer at TransThera, said in a press release. “We have been and will continue to actively work with FDA, expediting the clinical development of TT-00420 in CCA field.”
TT-00420 has demonstrated high potency in a variety of FGFR2-mutant diseases in preclinical research. Additionally, its molecular profile and mechanism of action allow for the treatment of heterogeneous tumors, including patients who do not have clear markers.
The phase 1 first-in-human dose escalation and expansion trial included 40 patients who were treated with 1 of 7 doses of TT-00420 at 1 mg, 3 mg, 5 mg, 8 mg, 10 mg, 12 mg, and 15 mg daily.
Among evaluable patients, 5 had an FGFR fusion or rearrangement and resistance to a prior FGFR inhibitor. One patient in the cholangiocarcinoma cohort achieved a PR within approximately 10 months. Additionally, 1 responder had a progression-free survival time of 8 months and another without an FGFR alteration achieved stable disease with a reduction in tumor size.
The most common suspected adverse effects (AEs) at any-grade included hypertension (42.5%), diarrhea (25.0%), vomiting (22.5%), palmar-plantar erythrodysaesthesia syndrome (22.5%), and nausea (20.0%). Additionally, the most common grade 3 AEs were hypertension (20.0%), diarrhea (2.5%), palmar-plantar erythrodysaesthesia syndrome (2.5%), and nausea (2.5%).
TT-00420 was previously granted an orphan drug designation by the FDA in November 2019.
Sintilimab Combo Shows Modest Efficacy, Safety in HER2– Gastric/GEJ Cancer
February 18th 2024Over half of the patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma achieve a major pathological complete response following treatment with sintilimab plus FLOT in a phase 2 trial.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Fruquintinib/Paclitaxel Improves PFS, ORR in Gastric/GEJ Adenocarcinoma
February 7th 2024Findings from the FRUTIGA study support fruquintinib plus paclitaxel as a promising second-line treatment for those with advanced gastric or gastroesophageal junction adenocarcinoma following prior chemotherapy.